Schonfeld Strategic Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$330K Sell
10,538
-12,416
-54% -$389K ﹤0.01% 1573
2025
Q1
$770K Buy
22,954
+7,804
+52% +$262K ﹤0.01% 1277
2024
Q4
$594K Buy
15,150
+1,568
+12% +$61.5K ﹤0.01% 1263
2024
Q3
$535K Sell
13,582
-18,678
-58% -$735K ﹤0.01% 1267
2024
Q2
$1.26M Sell
32,260
-47,691
-60% -$1.86M 0.01% 986
2024
Q1
$3.44M Sell
79,951
-7,549
-9% -$325K 0.02% 645
2023
Q4
$4.03M Sell
87,500
-111,484
-56% -$5.13M 0.03% 519
2023
Q3
$6.8M Buy
198,984
+18,841
+10% +$644K 0.05% 404
2023
Q2
$6.94M Sell
180,143
-119,976
-40% -$4.62M 0.06% 425
2023
Q1
$10.7M Buy
300,119
+131,706
+78% +$4.71M 0.1% 267
2022
Q4
$6.64M Buy
168,413
+60,129
+56% +$2.37M 0.06% 403
2022
Q3
$3.91M Sell
108,284
-19,825
-15% -$716K 0.03% 613
2022
Q2
$3.9M Buy
128,109
+25,735
+25% +$783K 0.04% 496
2022
Q1
$3.13M Buy
102,374
+13,474
+15% +$412K 0.03% 535
2021
Q4
$2.78M Sell
88,900
-31,221
-26% -$975K 0.03% 563
2021
Q3
$1.84M Buy
120,121
+23,521
+24% +$360K 0.02% 683
2021
Q2
$1.8M Buy
96,600
+13,200
+16% +$246K 0.02% 720
2021
Q1
$1.49M Buy
83,400
+10,800
+15% +$193K 0.02% 722
2020
Q4
$1.12M Buy
72,600
+10,000
+16% +$154K 0.02% 736
2020
Q3
$693K Buy
62,600
+27,000
+76% +$299K 0.01% 774
2020
Q2
$447K Buy
35,600
+22,600
+174% +$284K 0.01% 802
2020
Q1
$147K Sell
13,000
-56,400
-81% -$638K 0.01% 963
2019
Q4
$910K Buy
+69,400
New +$910K 0.02% 541
2019
Q2
Sell
-500,000
Closed -$5.08M 1268
2019
Q1
$5.08M Buy
500,000
+9,942
+2% +$101K 0.18% 156
2018
Q4
$3.09M Sell
490,058
-72,355
-13% -$457K 0.12% 235
2018
Q3
$7.42M Buy
562,413
+107,413
+24% +$1.42M 0.33% 74
2018
Q2
$4.19M Buy
455,000
+70,000
+18% +$644K 0.23% 153
2018
Q1
$1.89M Hold
385,000
0.14% 209
2017
Q4
$1.09M Buy
385,000
+110,000
+40% +$311K 0.09% 294
2017
Q3
$811K Buy
275,000
+150,000
+120% +$442K 0.07% 296
2017
Q2
$394K Buy
+125,000
New +$394K 0.04% 432